By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively. View our Privacy Policy for more information. Accept

News

March 16, 2022

AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors

February 16, 2022

AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria

February 10, 2022

AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole

January 20, 2022

AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease

January 7, 2022

AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

November 21, 2019

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

For Media and Investor inquiries please contact info@an2therapeutics.com